Latest & greatest articles for aripiprazole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aripiprazole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aripiprazole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for aripiprazole

1. Aripiprazole

Aripiprazole Top results for aripiprazole - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for aripiprazole The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

2. Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation). (PubMed)

Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation). People experiencing psychosis may become aggressive. Antipsychotics, such as aripiprazole in intramuscular form, can be used in such situations.To evaluate the effects of intramuscular aripiprazole in the treatment of psychosis-induced aggression or agitation (rapid tranquillisation).On 11 December 2014 and 11 April 2017, we searched the Cochrane Schizophrenia Group's Study-based Register (...) of Trials which is based on regular searches of CINAHL, BIOSIS, AMED, Embase, PubMed, MEDLINE, PsycINFO, and registries of clinical trials.All randomised controlled trials (RCTs) that randomised people with psychosis-induced aggression or agitation to receive either intramuscular aripiprazole or another intramuscular intervention.We independently inspected citations and, where possible, abstracts, ordered papers and re-inspected and quality assessed these. We included studies that met our selection

2018 Cochrane

3. Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial. (PubMed)

Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial. Hyperprolactinaemia is a troublesome side-effect of treatment with antipsychotics.This double-blind, placebo-controlled study aimed at examining the effect of adjunctive treatment with 10 mg aripiprazole on prolactin levels and sexual side-effects in patients with schizophrenia symptomatically maintained on risperidone.Thirty patients taking risperidone were enrolled (...) into the trial (CTRI/2012/11/003114). Aripiprazole was administered at a fixed daily dose of 10 mg/day for 8 weeks. Serum prolactin was measured at baseline and at 8 weeks. Hyperprolactinaemia-related problems, psychopathology and side-effects were evaluated every 2 weeks.Prolactin levels decreased by 58% in the aripiprazole group compared with an increase by 22% in the placebo group. Prolactin levels normalised in 46% of patients in the aripiprazole group (number needed to treat, NNT=2). Aripiprazole

Full Text available with Trip Pro

2016 BJPsych open

4. Aripiprazole for autism spectrum disorders (ASD). (PubMed)

Aripiprazole for autism spectrum disorders (ASD). Autism spectrum disorders (ASD) include autistic disorder, Asperger's disorder and pervasive developmental disorder - not otherwise specified (PDD-NOS). Antipsychotics have been used as a medication intervention for irritability related to ASD. Aripiprazole, a third-generation, atypical antipsychotic, is a relatively new drug that has a unique mechanism of action different from that of other antipsychotics. This review updates a previous (...) Cochrane review on the safety and efficacy of aripiprazole for individuals with ASD, published in 2011 (Ching 2011).To assess the safety and efficacy of aripiprazole as medication treatment for individuals with ASD.In October 2015, we searched the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL) and seven other databases as well as two trial registers. We searched for records published in 1990 or later

Full Text available with Trip Pro

2016 Cochrane

5. Aripiprazole for Patients with Bipolar Disorder: A Review of the Clinical Effectiveness, Cost-effectiveness and Guidelines

Aripiprazole for Patients with Bipolar Disorder: A Review of the Clinical Effectiveness, Cost-effectiveness and Guidelines Aripiprazole for Patients with Bipolar Disorder: A Review of the Clinical Effectiveness, Cost-effectiveness and Guidelines | CADTH.ca Find the information you need Aripiprazole for Patients with Bipolar Disorder: A Review of the Clinical Effectiveness, Cost-effectiveness and Guidelines Aripiprazole for Patients with Bipolar Disorder: A Review of the Clinical Effectiveness (...) , Cost-effectiveness and Guidelines Published on: May 25, 2016 Project Number: RC0780-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical efficacy of aripiprazole alone or as part of combination therapy for the treatment of bipolar disorder? What is the cost-effectiveness of aripiprazole alone or as part of combination therapy for the treatment of bipolar disorder? What are the evidence-based guidelines regarding the use

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

6. The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review. (PubMed)

The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review. Bipolar disorder is characterized by exacerbations of opposite mood polarity, ranging from manic to major depressive episodes. In the current nosological system of the Diagnostic and Statistical Manual - 5(th) edition (DSM-5), it is conceptualized as a spectrum disorder consisting of bipolar disorder type I, bipolar disorder type II, cyclothymic disorder, and bipolar disorder not otherwise specified. Treatment (...) of all phases of this disorder is primarily with mood stabilizers, but many patients either show resistance to the conventional mood stabilizing medications or are intolerant to their side-effects. In this setting, second-generation antipsychotics have gained prominence as many bipolar subjects who are otherwise treatment refractory show response to these agents. Aripiprazole is a novel antipsychotic initially approved for the treatment of schizophrenia but soon found to be effective in bipolar

Full Text available with Trip Pro

2016 Curēus

7. Aripiprazole as an Adjunct to Anti-depressants for Major Depressive Disorder: Clinical Effectiveness, Cost-effectiveness, and Guidelines

Aripiprazole as an Adjunct to Anti-depressants for Major Depressive Disorder: Clinical Effectiveness, Cost-effectiveness, and Guidelines Aripiprazole as an Adjunct to Anti-depressants for Major Depressive Disorder: Clinical Effectiveness, Cost-effectiveness, and Guidelines | CADTH.ca Find the information you need Aripiprazole as an Adjunct to Anti-depressants for Major Depressive Disorder: Clinical Effectiveness, Cost-effectiveness, and Guidelines Aripiprazole as an Adjunct to Anti-depressants (...) for Major Depressive Disorder: Clinical Effectiveness, Cost-effectiveness, and Guidelines Published on: May 4, 2016 Project Number: RA0846-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question 1. What is the clinical efficacy of aripiprazole as an adjunct to antidepressants for the treatment of patients with major depressive disorder who have had an inadequate response to prior antidepressant treatments? 2. What is the cost-effectiveness of aripiprazole

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Pharmacological interventions: Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia?

Pharmacological interventions: Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia? Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia? | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia? Article Text Further commentaries Electronic pages

2016 Evidence-Based Mental Health

9. Aristada (aripiprazole lauroxil) - To treat adults with schizophrenia

Aristada (aripiprazole lauroxil) - To treat adults with schizophrenia Aristada (aripiprazole lauroxil) U.S. Department of Health and Human Services Search FDA Submit search Aristada (aripiprazole lauroxil) Aristada (aripiprazole lauroxil) Company: Alkermes, Inc. Application No.: 207533 Approval Date: October 5, 2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2015 FDA - Drug Approval Package

10. Aripiprazole Sandoz

Aripiprazole Sandoz 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 25 June 2015 EMA/CHMP/512637/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Aripiprazole Sandoz International non-proprietary name: aripiprazole Procedure No. EMEA/H/C/004008/0000 Note Assessment report as adopted by the CHMP (...) /30 1. Background information on the procedure 1.1. Submission of the dossier The applicant Sandoz GmbH submitted on 10 June 2014 an application for Marketing Authorisation to the European Medicines Agency (EMA) for Aripiprazole Sandoz, through the centralised procedure under Article 3 (3) of Regulation (EC) No. 726/2004– ‘Generic of a Centrally authorised product’. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 25 April 2015. The application concerns a generic

2015 European Medicines Agency - EPARs

11. Aripiprazole Mylan - aripiprazole

Aripiprazole Mylan - aripiprazole 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. 20 November 2014 EMA/CHMP/705827/2014 Committee for Medicinal Products for Human Use (CHMP) Withdrawal Assessment report Aripiprazole Mylan (...) International non-proprietary name: aripiprazole Procedure No. EMEA/H/C/003926 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Aripiprazole Mylan EMA/CHMP/705827/2014 Page 2/39 Table of contents 1. Recommendation 3 Questions to be posed to additional experts 3 Inspection issues 3 2. Executive summary 4 2.1. Problem statement 4 2.2. About the product 4 2.3. The development programme/Compliance with CHMP Guidance/Scientific Advice 8 2.4

2015 European Medicines Agency - EPARs

12. Aripiprazole Zentiva

Aripiprazole Zentiva 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 23 April 2015 EMA/CHMP/232319/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Aripiprazole Zentiva International non-proprietary name: aripiprazole Procedure No. EMEA/H/C/003899/0000 Note Assessment report as adopted by the CHMP (...) with all information of a commercially confidential nature deleted. Assessment report EMA/CHMP/232319/2015 Page 2/36 Administrative information Name of the medicinal product: Aripiprazole Zentiva Applicant: Zentiva, k.s. U Kabelovny 130 Praha 10 102 37 Czech Republic Active substance: aripiprazole International Non-proprietary Name: aripiprazole Pharmaco-therapeutic group (ATC Code): Antipsychotics, other antipsychotics (N05AX12) Therapeutic indication(s): ? Treatment of schizophrenia in adults

2015 European Medicines Agency - EPARs

13. Aripiprazole Accord (aripiprazole)

Aripiprazole Accord (aripiprazole) 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 24 September 2015 EMA/CHMP/523618/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Aripiprazole Accord International non-proprietary name: aripiprazole Procedure No. EMEA/H/C/004021/0000 Note Assessment report (...) Page 5/26 1. Background information on the procedure 1.1. Submission of the dossier The applicant Accord Healthcare Ltd submitted on 1 August 2014 an application for Marketing Authorisation to the European Medicines Agency (EMA) for Aripiprazole Accord, through the centralised procedure under Article 3 (3) of Regulation (EC) No. 726/2004– ‘Generic of a Centrally authorised product’. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 22 May 2014. The application concerns

2015 European Medicines Agency - EPARs

14. Aripiprazole Pharmathen (aripiprazole)

Aripiprazole Pharmathen (aripiprazole) 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 23 April 2015 EMA/CHMP/747323/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Aripiprazole Pharmathen International non-proprietary name: aripiprazole Procedure No. EMEA/H/C/003803/0000 Note Assessment report (...) as adopted by the CHMP with all information of a commercially confidential nature deleted. EMA/CHMP/747323/2015 Page 2/26 Administrative information Name of the medicinal product: Aripiprazole Pharmathen Applicant: Pharmathen S.A. 6 Dervenakion str. Pallini 153 51 Athens GREECE Active substance: aripiprazole International Nonproprietary Name: aripiprazole Pharmaco-therapeutic group (ATC Code): Antipsychotics, other antipsychotics (N05AX12) Therapeutic indication(s): • Treatment of schizophrenia in adults

2015 European Medicines Agency - EPARs

15. Aripiprazole monohydrate (Abilify Maintena®)

Aripiprazole monohydrate (Abilify Maintena®) Aripiprazole monohydrate (Abilify Maintena®) Aripiprazole monohydrate (Abilify Maintena®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Aripiprazole monohydrate (Abilify Maintena®) Penarth: All Wales Therapeutics and Toxicology (...) Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2214. 2014 Authors' conclusions Aripiprazole (Abilify Maintena®) 400 mg powder and solvent for prolonged released suspension for injection is recommended as an option for use within NHS Wales for the maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Delayed

2015 Health Technology Assessment (HTA) Database.

16. Aripiprazole monohydrate (Abilify Maintena) - for the maintenance treatment of schizophrenia in adult patients stabilised with oral arip

Aripiprazole monohydrate (Abilify Maintena) - for the maintenance treatment of schizophrenia in adult patients stabilised with oral arip Final Appraisal Recommendation Advice No: 2214 – July 2014 Aripiprazole (Abilify Maintena ® ) 400 mg powder and solvent for prolonged release suspension for injection Submission by Otsuka Pharmaceuticals (UK) Ltd and Lundbeck Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (...) and Lundbeck Ltd Date of first issue July 2014 Last reviewed September 2017 Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2214: Aripiprazole (Abilify Maintena ® ) 400 mg powder and solvent for prolonged release suspension for injection. July 2014. Recommendation of AWMSG Aripiprazole (Abilify Maintena ® ) 400 mg powder and solvent for prolonged

2014 All Wales Medicines Strategy Group

17. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data

Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have (...) -effectiveness of lurasidone, compared with aripiprazole, for treating adult patients with schizophrenia, who had failed to respond to generic atypical antipsychotics. The authors concluded that lurasidone was less costly and more effective than aripiprazole. The results and modelling were well reported, but given the uncertainty around the use of all the best evidence available, the authors' conclusions may need to be interpreted with caution. Type of economic evaluation Cost-effectiveness analysis Study

2014 NHS Economic Evaluation Database.

18. Schizophrenia: aripiprazole prolonged-release suspension for injection

Schizophrenia: aripiprazole prolonged-release suspension for injection Schizophrenia: aripipr Schizophrenia: aripiprazole prolonged-release azole prolonged-release suspension for injection suspension for injection Evidence summary Published: 26 March 2014 nice.org.uk/guidance/esnm39 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in March 2014. See summaries of product characteristics (SPCs), British national formulary (...) (BNF) or the MHRA or NICE websites for up-to-date information. Summary Aripiprazole prolonged-release suspension for injection is licensed for maintenance treatment of schizophrenia in adults whose condition has been stabilised with oral aripiprazole. It was launched in the UK in January 2014. In 2 double-blind, randomised controlled trials (RCTs; n=403 and n=662), once-monthly aripiprazole 400 mg prolonged-release injection was shown to be superior to placebo and non-inferior to oral aripiprazole

2014 National Institute for Health and Clinical Excellence - Advice

19. Aripiprazole

Aripiprazole USE OF ARIPIPRAZOLE IN PREGNANCY 0344 892 0909 USE OF ARIPIPRAZOLE IN PREGNANCY (Date of issue: March 2015 , Version: 2.1 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Aripiprazole is an atypical antipsychotic used (...) in the treatment of schizophrenia, manic episodes, bipolar disorder, and other psychoses. There are only two small cohort studies which specifically investigate the use of aripiprazole in pregnancy. Although aripiprazole exposures are included in a number of other studies which report on fetal outcome of women exposed to various antipsychotics, aripiprazole exposures generally represent only a small proportion of the study cohort and were not analysed separately. Human pregnancy data for aripiprazole are thus

2014 UK Teratology Information Service

20. Aripiprazole for pregnant women: safety

Aripiprazole for pregnant women: safety Aripiprazole for pregnant women: safety Aripiprazole for pregnant women: safety Canadian Agency for Drugs and Technologies in Health (CADTH) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health (CADTH). Aripiprazole for pregnant women: safety. Ottawa (...) : Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Respose - Summary of Abstracts. 2014 Authors' conclusions One non-randomized study was identified regarding the safety and harms of aripiprazole in pregnant women. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antipsychotic Agents; Congenital Abnormalitiesnic and Fetal Development; Fetus; Maternal Exposure; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Teratogenss Language Published English

2014 Health Technology Assessment (HTA) Database.